Literature DB >> 26849037

Targeting the tumour microenvironment in ovarian cancer.

Jean M Hansen1, Robert L Coleman2, Anil K Sood3.   

Abstract

The study of cancer initiation, growth, and metastasis has traditionally been focused on cancer cells, and the view that they proliferate due to uncontrolled growth signalling owing to genetic derangements. However, uncontrolled growth in tumours cannot be explained solely by aberrations in cancer cells themselves. To fully understand the biological behaviour of tumours, it is essential to understand the microenvironment in which cancer cells exist, and how they manipulate the surrounding stroma to promote the malignant phenotype. Ovarian cancer is the leading cause of death from gynaecologic cancer worldwide. The majority of patients will have objective responses to standard tumour debulking surgery and platinum-taxane doublet chemotherapy, but most will experience disease recurrence and chemotherapy resistance. As such, a great deal of effort has been put forth to develop therapies that target the tumour microenvironment in ovarian cancer. Herein, we review the key components of the tumour microenvironment as they pertain to this disease, outline targeting opportunities and supporting evidence thus far, and discuss resistance to therapy.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ovarian cancer; Tumour microenvironment

Mesh:

Substances:

Year:  2016        PMID: 26849037      PMCID: PMC4769921          DOI: 10.1016/j.ejca.2015.12.016

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  143 in total

Review 1.  Myofibroblasts and mechano-regulation of connective tissue remodelling.

Authors:  James J Tomasek; Giulio Gabbiani; Boris Hinz; Christine Chaponnier; Robert A Brown
Journal:  Nat Rev Mol Cell Biol       Date:  2002-05       Impact factor: 94.444

2.  Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines.

Authors:  R P Negus; G W Stamp; J Hadley; F R Balkwill
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  Cancer associated fibroblasts: the dark side of the coin.

Authors:  Paolo Cirri; Paola Chiarugi
Journal:  Am J Cancer Res       Date:  2011-03-12       Impact factor: 6.166

4.  Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta.

Authors:  M H Sieweke; N L Thompson; M B Sporn; M J Bissell
Journal:  Science       Date:  1990-06-29       Impact factor: 47.728

5.  Prognostic models in melanoma.

Authors:  A C Halpern; L M Schuchter
Journal:  Semin Oncol       Date:  1997-02       Impact factor: 4.929

Review 6.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

7.  Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis.

Authors:  Hippokratis Kiaris; Ioulia Chatzistamou; George Trimis; Matrisa Frangou-Plemmenou; Agatha Pafiti-Kondi; Anastasios Kalofoutis
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

8.  Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.

Authors:  Sarah F Adams; Douglas A Levine; Mark G Cadungog; Rachel Hammond; Andrea Facciabene; Narciso Olvera; Stephen C Rubin; Jeff Boyd; Phyllis A Gimotty; George Coukos
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

9.  VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism.

Authors:  Hans-Peter Gerber; Ajay K Malik; Gregg P Solar; Daniel Sherman; Xiao Huan Liang; Gloria Meng; Kyu Hong; James C Marsters; Napoleone Ferrara
Journal:  Nature       Date:  2002-06-27       Impact factor: 49.962

10.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

View more
  43 in total

Review 1.  Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients.

Authors:  Caroline Lum; Christopher B Steer
Journal:  Drugs Aging       Date:  2017-11       Impact factor: 3.923

Review 2.  Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review.

Authors:  Eric R Craig; Angelina I Londoño; Lyse A Norian; Rebecca C Arend
Journal:  Gynecol Oncol       Date:  2016-10-15       Impact factor: 5.482

3.  Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis.

Authors:  Hilary A Kenny; Madhu Lal-Nag; Min Shen; Betul Kara; Dominik A Nahotko; Kristen Wroblewski; Sarah Fazal; Siquan Chen; Chun-Yi Chiang; Yen-Ju Chen; Kyle R Brimacombe; Juan Marugan; Marc Ferrer; Ernst Lengyel
Journal:  Mol Cancer Ther       Date:  2019-09-27       Impact factor: 6.261

4.  Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth.

Authors:  Lifeng Yang; Abhinav Achreja; Tsz-Lun Yeung; Lingegowda S Mangala; Dahai Jiang; Cecil Han; Joelle Baddour; Juan C Marini; Joseph Ni; Ryuichi Nakahara; Stephen Wahlig; Lisa Chiba; Sun Hye Kim; Joshua Morse; Sunila Pradeep; Archana Sidalaghatta Nagaraja; Monika Haemmerle; Noh Kyunghee; Mathew Derichsweiler; Thomas Plackemeier; Imelda Mercado-Uribe; Gabriel Lopez-Berestein; Tyler Moss; Prahlad T Ram; Jinsong Liu; Xiongbin Lu; Samuel C Mok; Anil K Sood; Deepak Nagrath
Journal:  Cell Metab       Date:  2016-11-08       Impact factor: 27.287

5.  Berberine inhibits the chemotherapy-induced repopulation by suppressing the arachidonic acid metabolic pathway and phosphorylation of FAK in ovarian cancer.

Authors:  Yawei Zhao; Lianzhi Cui; Yue Pan; Dan Shao; Xiao Zheng; Fan Zhang; Hansi Zhang; Kan He; Li Chen
Journal:  Cell Prolif       Date:  2017-10-08       Impact factor: 6.831

Review 6.  Epigenetic control of the tumor microenvironment.

Authors:  David L Marks; Rachel Lo Olson; Martin E Fernandez-Zapico
Journal:  Epigenomics       Date:  2016-10-04       Impact factor: 4.778

7.  Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.

Authors:  Qing Zhang; Chen Wang; William A Cliby
Journal:  Gynecol Oncol       Date:  2018-11-15       Impact factor: 5.482

Review 8.  Metabolism shapes the tumor microenvironment.

Authors:  Miguel Reina-Campos; Jorge Moscat; Maria Diaz-Meco
Journal:  Curr Opin Cell Biol       Date:  2017-06-09       Impact factor: 8.382

Review 9.  MicroRNAs in gynecological cancers: Small molecules with big implications.

Authors:  Sanjeev K Srivastava; Aamir Ahmad; Haseeb Zubair; Orlandric Miree; Seema Singh; Rodney P Rocconi; Jennifer Scalici; Ajay P Singh
Journal:  Cancer Lett       Date:  2017-05-24       Impact factor: 8.679

10.  Platelet Derived Growth Factor BB: A "Must-have" Therapeutic Target "Redivivus" in Ovarian Cancer.

Authors:  Anca Maria Cimpean; Ionut Marcel Cobec; Raluca Amalia Ceaușu; Roxana Popescu; Anca Tudor; Marius Raica
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.